Yangbing Zhao MD, PhD

Dr. Yangbing Zhao brings UTC Therapeutics Inc. over 20 years of distinguished experience in T cell immunotherapy with a renowned list of accomplishments, including the successful development of multiple novel CAR-T pipelines and conducting leading research that generated over 50 publications and over 170 patent filings. Before co-founding UTC Therapeutics, Dr. Zhao was the Director of the T Cell Engineering Lab at the Center for Cellular Therapy Institute and an Adjunct Associate Professor of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania.

Dr. Zhao's research in cancer immunotherapies has led to remarkable advancements, such as the creation of Kymriah and Yescarta, known for their capability to cure hematological cancers. Additionally, Dr. Zhao discovered the power of mRNA CAR-T treatments and was the first to utilize CRISPR/CAS9 techniques in patient treatment in the U.S. Dr. Zhao also led multiple cutting-edge clinical research projects in Steven Rosenberg's lab at the National Institutes of Health from 2003 to 2009.